



Biotechnology Colloquium
at the I.I.B.E.A.A.
FOUNDATION FOR BIOMEDICAL RESEARCH
ACADEMY OF ATHENS

Biotechnology Start-ups: Facts and Fiction
Athens, Tuesday 11 July 2006

Program

-
- 09:00 – 09:30** **Registration**
At the I.I.B.E.A.A. auditorium entrance hall
- 09:30 – 09:45** **Opening Remarks**
Professor Gregory D. Skalkeas, Academician
President of the Board of Trustees, I.I.B.E.A.A.
Professor Spyros Artavanis-Tsakonas, PhD
Harvard Medical School; President, Fondation Santé
- 09:45 – 11:00** **Panel Session**
Moderator: Professor Spyros Artavanis-Tsakonas, PhD
- Biotech as a Product of Investment Strategies**
Stelios Papadopoulos, PhD
Vice Chairman, Cowen and Company; Chairman of the Board, Fondation Santé
- Seeing the Commercial Relevance of a Scientific Idea**
Professor Spyros Artavanis-Tsakonas, PhD
Harvard Medical School; President, Fondation Santé
- Nurturing a Start-up and Managing Growth**
George Scangos, PhD
President & CEO, Exelixis Inc.
- Doing a Start-up for a Second Time: The Jump from Academia**
Corey Goodman, PhD
Co-founder, President & CEO, Renovis, Inc.
- Allowing Your Scientific Assets to Define Your Strategy**
Kleanthis Xanthopoulos, PhD
Co-founder, President & CEO, Anadys Pharmaceuticals, Inc.
- The Oxygen of Start-ups: Making Deals**
Steven Holtzman
Co-founder and CEO, Infinity Pharmaceuticals
- 11:00 – 11:30** **Coffee Break**
- 11:30 – 13:00** **Round Table Discussion with Panelists and Audience**
Moderator: Stelios Papadopoulos, PhD
The panelists will discuss many issues, including:
- The commercial sustainability of scientific ideas
 - How the first financing comes about and what are longer term financial strategies
 - What venture capital is looking for today
 - The balance between research and market forces
 - The role of management and the culture of start-ups
 - Long range planning
 - Can and should Greece be considered for biotech start-ups
- 13:00 – 13:15** **Closing Remarks-** Professor Spyros Artavanis-Tsakonas, PhD



Panelists

Spyros Artavanis-Tsakonas, PhD is a Professor at the Department of Cell Biology at Harvard Medical School which he joined in 1998. He holds the Isselbacher-Schwartz Professorship at the MGH Cancer Center. He is also a Professor at the Collège de France, Paris, holding the chair of Developmental Biology and Genetics. In 1981 he joined the Yale University faculty where he stayed until 1998. Dr. Artavanis-Tsakonas was a Professor in the Departments of Cell Biology and Biology at Yale where he also served as the Director of the Biological Sciences Division and was a Howard Hughes Medical Institute Investigator.

Dr. Artavanis-Tsakonas holds a Masters Degree in Chemistry from the Eidgenössische Technische Hochschule (ETH) in Zurich and a PhD from Cambridge University, England for work carried out at the Medical Research Council Laboratory of Molecular Biology. He is a member of the American Academy of Arts and Sciences, corresponding member of the Athens Academy, and a member of the Cambridge Philosophical society.

Dr. Artavanis-Tsakonas has co-founded the biotechnology companies Exelixis, Inc., Cellzome, Inc., and Anadys Pharmaceuticals, Inc. He is also co-founder and President of Fondation Santé.

Corey S. Goodman, PhD has served as the President and Chief Executive Officer and a Director of Renovis, Inc. since September 2001. He co-founded Renovis in 2000 and previously co-founded Exelixis in 1994. Dr. Goodman was a professor at Stanford for eight years, and then at the University of California, for 18 years. Today he is an adjunct professor of neurobiology at U.C. Berkeley. At Berkeley, Dr. Goodman was the Evan Rauch Professor of Neuroscience, the Director and co-founder of the Wills Neuroscience Institute, and an Investigator with the Howard Hughes Medical Institute. Dr. Goodman was elected a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. Dr. Goodman's honors include the Alan T. Waterman Award in 1983, the Gairdner Award in 1997, and the March-of-Dimes Prize in 2001. Dr. Goodman is Chair of the National Research Council's Board of Life Sciences, Vice President of the McKnight Endowment Fund for Neuroscience, and a member of the BayBio board and the Biotechnology Industry Organization's ECS board. Dr. Goodman received a BS in Biology from Stanford University, a PhD in Neurobiology from the University of California, Berkeley, and was a postdoctoral fellow at the University of California, San Diego.

Steven H. Holtzman is a founder as well as the Chairman and Chief Executive Officer of Infinity Pharmaceuticals, Inc. Located in Cambridge, MA, Infinity is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients. From early 1994 until 2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals, Inc. a pioneer in the development and application of modern genetic and genomic technologies to drug discovery. Prior to joining Millennium and starting in 1986, Mr. Holtzman was a founder and the Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical and pharmaceutical applications of transgenic (genetically engineered) animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed at achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970's, he was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K.

Mr. Holtzman co-founded and from 1995 until 2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996 to 2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President of the United States and Congress on ethical issues in the biomedical and life sciences. He is a member of the Board of Directors of Anadys Pharmaceuticals, Inc., a Vice Chairman of the Board of Trustees of The Hastings Center for Ethics and the Life Sciences and a Trustee of the Berklee College of Music. Mr. Holtzman received his BA in Philosophy from Michigan State University and his BPhil graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.



Stelios Papadopoulos, PhD is a Vice Chairman of Cowen and Company, LLC and as an investment banker he focuses on the biotechnology and pharmaceutical sectors. Prior to joining Cowen in February 2000, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.

Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a PhD in biophysics and an MBA in finance, both from New York University.

Dr. Stelios Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and he is a co-founder and member of the Board of both, Anadys Pharmaceuticals, Inc. and Cellzome, Inc. He is also a member of the Board of Directors of GenVec, Inc. SGX Pharmaceuticals, Inc. and BG Medicine, Inc.

In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Directors of BIO Ventures for Global Health, a member of the Board of Governors of the New York Academy of Sciences and a member of the Board of Visitors of Duke University Medical Center.

George A. Scangos, PhD is President and Chief Executive Officer of Exelixis Inc. since October 1996. Dr. Scangos began his career on the faculty of the Johns Hopkins University, where he now holds an appointment as Adjunct Professor of Biology. He left Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology.

Dr. Scangos serves on the Boards of Directors of Anadys Pharmaceuticals, Inc., Entelos, Inc., as well as Exelixis. He serves on the Board of Visitors at the University of California, San Francisco School of Pharmacy, the Board of Overseers at the University of California, Davis Medical School, and the Advisory Board for the Cornell University Life Sciences Initiative.

Dr. Scangos received a BA from Cornell University, a PhD in Microbiology from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Frank Ruddle at Yale University

Kleanthis G. Xanthopoulos, PhD co-founded and was appointed President & CEO of Anadys Pharmaceuticals Inc. in May 2000 after serving as Vice President of Genomics & Molecular Biology at Aurora Biosciences Corp., where he developed and commercialized Aurora's genomics business. Prior to joining Aurora, Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at the National Institutes of Health (NIH). Previously, he held an Associate Professorship at the Karolinska Nobel Medical Institute, Stockholm, Sweden.

Dr. Xanthopoulos was an Onasis Scholar, a Greek Government Distinguished Fellow, the recipient of Swedish National Sciences Foundation awards and was a NIH Fellow at the Rockefeller University, New York. Additionally, Dr. Xanthopoulos graduated with honors from the Aristotle University of Thessaloniki, Greece and received both his MS in Microbiology and PhD in Molecular Biology from the University of Stockholm, Sweden.



Fondation Santé was established in 2000 as a private foundation operating exclusively for charitable, scientific and educational purposes. The foundation aims to assist in advancing the health and education of those in need, whether individuals, regions or countries.



Contact Information:

For more information about Fondation Santé and our activities, please contact:

info@fondationsante.org

Tel.: + 30 210 6754 831, Fax: + 30 210 6710 666

www.fondationsante.org

